Drug Profile
Research programme: cancer peptide vaccines - OncoTherapy Science/Shionogi
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator OncoTherapy Science; Shionogi
- Class Cancer vaccines; Peptide vaccines; Subunit vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer; Head and neck cancer; Lung cancer; Prostate cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Head-and-neck-cancer in Japan (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Lung-cancer in Japan (Parenteral)
- 30 Mar 2012 OncoTherapy Science and Shionogi expand their research collaboration for peptide cancer vaccines